Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Medical Oncology · HER2-Negative Breast Cancer

Staging and Genomic Risk Assessment

At a Glance

For HER2-negative breast cancer, doctors combine TNM stage, tumor grade, hormone receptor status, and HER2 status with genomic tests when appropriate. Oncotype DX and MammaPrint mainly help estimate chemotherapy benefit in early HR-positive/HER2-negative disease.

Once a diagnosis is confirmed, your care team must determine the “extent” of the cancer and its biological risk of returning. This process involves two distinct but related steps: anatomical staging, which describes where the cancer is located, and genomic risk profiling, which looks at the activity of the cancer’s genes to predict its behavior and chemotherapy benefit [1][2].

Anatomical Staging: The TNM System

The standard way to describe the physical extent of breast cancer is the TNM system [3]. You will see two versions: your clinical stage (cTNM), estimated from exams and imaging before surgery, and your pathologic stage (pTNM), based on the actual tissue removed during surgery.

  • T (Tumor): The size of the primary tumor. T4 specifically refers to invasion of the chest wall or skin (including inflammatory breast cancer), regardless of size [2].
  • N (Node): Whether the cancer has spread to nearby lymph nodes (N0 means no spread; N1–N3 describes the number and location of involved nodes) [2].
  • M (Metastasis): Whether the cancer has spread to distant organs, like the lungs or bones (M0 means it has not; M1 means it has) [2].

Modern staging also includes your tumor grade (how aggressive the cells look) and your biomarker status (ER, PR, and HER2) to create a “prognostic stage” that more accurately predicts outcomes than size alone [1][4].

Genomic Profiling for HR+/HER2- Cancer

For patients with early-stage Hormone Receptor-Positive (HR+), HER2-negative cancer, the physical stage is only half the story. Because these cancers are often slow-growing, doctors use multigene assays to see if chemotherapy provides a meaningful predictive benefit over hormone therapy alone [5].

Oncotype DX and the Recurrence Score

The most common test is Oncotype DX, which analyzes 21 genes in the tumor tissue to produce a Recurrence Score (RS) from 0 to 100 [6]. A lower score means a lower risk of the cancer returning and less benefit from chemotherapy [7].

Your age and menopausal status are critical when interpreting these scores:

  • If you are postmenopausal:
    • Node-Negative or 1–3 Positive Nodes: If your score is 0–25, based on the RxPONDER trial, postmenopausal women do not benefit from adding chemotherapy over hormone therapy alone [8][9].
  • If you are premenopausal (or age 50 and younger):
    • Node-Negative: If your score is 0–15, hormone therapy alone is usually recommended [10]. If your score is 16–25, there is a small absolute benefit to adding chemotherapy, which you should discuss with your doctor (some of this benefit may reflect chemotherapy-induced ovarian suppression) [8].
    • 1–3 Positive Nodes: Research shows that premenopausal women in this group generally benefit from chemotherapy regardless of their Recurrence Score [9][5].

(Scores above 25 indicate a higher risk where chemotherapy is generally recommended).

Other Tests: MammaPrint

MammaPrint is another assay that classifies tumors as “Low Risk” or “High Risk” [11]. It is used in selected early-stage HR+/HER2- cases to help decide if chemotherapy can be safely avoided when clinical features make the decision unclear, with more uncertainty about chemotherapy benefit in younger patients [5][12].

Why TNBC is Different

If you have Triple-Negative Breast Cancer (TNBC), your doctor will not use Oncotype DX or MammaPrint. These tests were designed specifically for hormone-driven cancers and do not accurately predict chemotherapy benefit for TNBC [13][14].

For TNBC, treatment decisions are based strictly on anatomical factors combined with age, health, and patient preferences:

  • Tumor Size and Nodal Status: Because TNBC is generally more aggressive, chemotherapy is standard for T1c disease (larger than 1 cm) or any cancer that has spread to the lymph nodes [13]. For T1b tumors (greater than 0.5 cm to 1 cm), chemotherapy is commonly considered on an individualized basis.
  • Biological Markers: Rather than multigene scores, your team will look at markers like germline BRCA mutations. A marker called PD-L1 is also tested, but principally to guide immunotherapy selection in the metastatic setting, not early-stage [15][16].

These assays are powerful tools, but they are not the only factors in your care. Your doctor will combine your genomic results with your physical stage, health history, and personal preferences to build your treatment plan [17].

Common questions in this guide

What do T, N, and M mean in breast cancer staging?
T describes the size or local extension of the primary tumor, N describes nearby lymph-node involvement, and M describes spread to distant organs. Clinical stage, or cTNM, is estimated before surgery, while pathologic stage, or pTNM, is based on tissue removed during surgery.
What is the difference between an anatomical stage and a prognostic stage?
Anatomical stage uses tumor size, lymph-node involvement, and distant spread. Prognostic stage also considers tumor grade and ER, PR, and HER2 results to provide a more individualized estimate of outlook.
Who may benefit from an Oncotype DX test?
Oncotype DX is mainly used for selected people with early-stage, hormone receptor-positive, HER2-negative breast cancer. It estimates recurrence risk and whether chemotherapy is likely to add meaningful benefit to hormone therapy, but the result must be interpreted with age, menopausal status, tumor features, and lymph-node status.
How does my Oncotype DX Recurrence Score affect the chemotherapy decision?
The Recurrence Score ranges from 0 to 100; a lower score generally means lower recurrence risk and less expected benefit from chemotherapy. In postmenopausal patients with no involved lymph nodes or one to three involved nodes, a score of 0–25 generally does not add chemotherapy benefit over hormone therapy alone. In premenopausal patients, a node-negative score of 0–15 often supports hormone therapy alone, while scores of 16–25 may offer a small chemotherapy benefit. Patients with one to three positive nodes generally benefit from chemotherapy regardless of score.
What does a MammaPrint result tell me?
MammaPrint classifies selected early-stage hormone receptor-positive, HER2-negative tumors as having lower or higher genomic risk. It can help when clinical features make the chemotherapy decision uncertain, but its ability to predict chemotherapy benefit is less certain in younger patients.
Can Oncotype DX or MammaPrint be used for triple-negative breast cancer?
These tests are designed for hormone receptor-positive, HER2-negative cancers and do not accurately predict chemotherapy benefit in triple-negative breast cancer. For triple-negative disease, decisions rely more on tumor size, lymph-node status, age, overall health, and patient preferences, with selected biomarkers helping guide particular treatments.
What factors guide treatment for early triple-negative breast cancer?
Chemotherapy is generally standard for a triple-negative tumor larger than 1 centimeter or for cancer involving lymph nodes, while tumors larger than 0.5 centimeter but no more than 1 centimeter are considered individually. Germline BRCA testing can inform care, and PD-L1 testing is used mainly to help select immunotherapy in metastatic disease rather than for early-stage decisions.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my clinical stage (cTNM) compared to my pathologic stage (pTNM)?
  2. 2.If I have HR-positive cancer, is an Oncotype DX or MammaPrint test appropriate for my specific nodal status, tumor size, and age?
  3. 3.Based on my menopausal status and Recurrence Score, what is the estimated absolute benefit (in percentage) that chemotherapy would add to my hormone therapy?
  4. 4.For my HR-positive cancer, how do my tumor grade and lymphovascular invasion factor into the genomic test results when deciding on chemotherapy?
  5. 5.If I have TNBC, what specific factors (like tumor size and nodal status) are you using to determine my chemotherapy and local treatment plan?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    New and Important Changes in the TNM Staging System for Breast Cancer.

    Hortobagyi GN, Edge SB, Giuliano A

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2018; (38()):457-467 doi:10.1200/EDBK_201313.

    PMID: 30231399
  2. 2

    Breast Cancer Staging: Updates in the AJCC Cancer Staging Manual, 8th Edition, and Current Challenges for Radiologists, From the AJR Special Series on Cancer Staging.

    Teichgraeber DC, Guirguis MS, Whitman GJ

    AJR. American journal of roentgenology 2021; (217(2)):278-290 doi:10.2214/AJR.20.25223.

    PMID: 33594908
  3. 3

    The new TNM-based staging of breast cancer.

    Cserni G, Chmielik E, Cserni B, Tot T

    Virchows Archiv : an international journal of pathology 2018; (472(5)):697-703 doi:10.1007/s00428-018-2301-9.

    PMID: 29380126
  4. 4

    Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer.

    Weiss A, Chavez-MacGregor M, Lichtensztajn DY, et al.

    JAMA oncology 2018; (4(2)):203-209 doi:10.1001/jamaoncol.2017.4298.

    PMID: 29222540
  5. 5

    Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.

    Andre F, Ismaila N, Allison KH, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(16)):1816-1837 doi:10.1200/JCO.22.00069.

    PMID: 35439025
  6. 6

    Clinical evidence supporting genomic tests in early breast cancer: Do all genomic tests provide the same information?

    Markopoulos C, van de Velde C, Zarca D, et al.

    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2017; (43(5)):909-920 doi:10.1016/j.ejso.2016.08.012.

    PMID: 27639633
  7. 7

    Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

    Sparano JA, Gray RJ, Makower DF, et al.

    The New England journal of medicine 2015; (373(21)):2005-14 doi:10.1056/NEJMoa1510764.

    PMID: 26412349
  8. 8

    Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

    Sparano JA, Gray RJ, Makower DF, et al.

    The New England journal of medicine 2018; (379(2)):111-121 doi:10.1056/NEJMoa1804710.

    PMID: 29860917
  9. 9

    21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.

    Kalinsky K, Barlow WE, Gralow JR, et al.

    The New England journal of medicine 2021; (385(25)):2336-2347 doi:10.1056/NEJMoa2108873.

    PMID: 34914339
  10. 10

    Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.

    Andre F, Ismaila N, Henry NL, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(22)):1956-1964 doi:10.1200/JCO.19.00945.

    PMID: 31150316
  11. 11

    Prognostic and predictive biomarkers in breast cancer: Past, present and future.

    Nicolini A, Ferrari P, Duffy MJ

    Seminars in cancer biology 2018; (52(Pt 1)):56-73 doi:10.1016/j.semcancer.2017.08.010.

    PMID: 28882552
  12. 12

    Gene expression profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer: a systematic review.

    Cooper K, Nalbant G, Essat M, et al.

    Breast cancer research and treatment 2025; (210(2)):229-247 doi:10.1007/s10549-024-07596-0.

    PMID: 39899163
  13. 13

    Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.

    Korde LA, Somerfield MR, Carey LA, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(13)):1485-1505 doi:10.1200/JCO.20.03399.

    PMID: 33507815
  14. 14

    Gene signature-based prediction of triple-negative breast cancer patient response to Neoadjuvant chemotherapy.

    Zhao Y, Schaafsma E, Cheng C

    Cancer medicine 2020; (9(17)):6281-6295 doi:10.1002/cam4.3284.

    PMID: 32692484
  15. 15

    Progress in immune checkpoint inhibition in early-stage triple-negative breast cancer.

    Mohamed A, Kruse M, Tran J

    Expert review of anticancer therapy 2023; (23(10)):1071-1084 doi:10.1080/14737140.2023.2262764.

    PMID: 37747062
  16. 16

    Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.

    Bedrosian I, Somerfield MR, Achatz MI, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024; (42(5)):584-604 doi:10.1200/JCO.23.02225.

    PMID: 38175972
  17. 17

    Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.

    Caswell-Jin JL, Somerfield MR, Khan MA, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2026; 101200JCO2602034 doi:10.1200/JCO-26-02034.

    PMID: 42647767

This page is for informational purposes only and does not constitute medical advice. Your oncology team should interpret your TNM stage and genomic results and discuss the likely benefits and risks of treatment for your specific situation.

Get notified when new evidence is published on Her2-receptor negative breast cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.